Literature DB >> 9753305

Prevalence of insulin resistance in metabolic disorders: the Bruneck Study.

E Bonora1, S Kiechl, J Willeit, F Oberhollenzer, G Egger, G Targher, M Alberiche, R C Bonadonna, M Muggeo.   

Abstract

The prevalence of insulin resistance in the most common metabolic disorders is still an undefined issue. We assessed the prevalence rates of insulin resistance in subjects with impaired glucose tolerance (IGT), NIDDM, dyslipidemia, hyperuricemia, and hypertension as identified within the frame of the Bruneck Study. The study comprised an age- and sex-stratified random sample of the general population (n = 888; aged 40-79 years). Insulin resistance was estimated by homeostasis model assessment (HOMA(IR)), preliminarily validated against a euglycemic-hyperinsulinemic clamp in 85 subjects. The lower limit of the top quintile of HOMA(IR) distribution (i.e., 2.77) in nonobese subjects with no metabolic disorders (n = 225) was chosen as the threshold for insulin resistance. The prevalence of insulin resistance was 65.9% in IGT subjects, 83.9% in NIDDM subjects, 53.5% in hypercholesterolemia subjects, 84.2% in hypertriglyceridemia subjects, 88.1% in subjects with low HDL cholesterol, 62.8% in hyperuricemia subjects, and 58.0% in hypertension subjects. The prevalence of insulin resistance in subjects with the combination of glucose intolerance (IGT or NIDDM), dyslipidemia (hypercholesterolemia and/or hypertriglyceridemia and/or low HDL cholesterol), hyperuricemia, and hypertension (n = 21) was 95.2%. In isolated hypercholesterolemia, hypertension, or hyperuricemia, prevalence rates of insulin resistance were not higher than that in nonobese normal subjects. An appreciable number of subjects (n = 85, 9.6% of the whole population) was insulin resistant but free of IGT, NIDDM, dyslipidemia, hyperuricemia, and hypertension. These results from a population-based study documented that 1) in hypertriglyceridemia and a low HDL cholesterol state, insulin resistance is as common as in NIDDM, whereas it is less frequent in hypercholesterolemia, hyperuricemia, and hypertension; 2) the vast majority of subjects with multiple metabolic disorders are insulin resistant; 3) in isolated hypercholesterolemia, hyperuricemia, or hypertension, insulin resistance is not more frequent than can be expected by chance alone; and 4) in the general population, insulin resistance can be found even in the absence of any major metabolic disorders.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9753305     DOI: 10.2337/diabetes.47.10.1643

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  164 in total

Review 1.  Insulin resistance and cardiovascular disease.

Authors:  H N Ginsberg
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

2.  Homeostasis model assessment of insulin resistance and the risk of cardiovascular events in middle-aged non-diabetic Japanese men.

Authors:  K Nakamura; M Sakurai; K Miura; Y Morikawa; M Ishizaki; K Yoshita; T Kido; Y Naruse; H Nakagawa
Journal:  Diabetologia       Date:  2010-05-26       Impact factor: 10.122

3.  The metabolically healthy but obese phenotype in African Americans.

Authors:  Rabia Cherqaoui; Thaslim A Kassim; John Kwagyan; Clyde Freeman; Gail Nunlee-Bland; Muluemebet Ketete; Shichen Xu; Otelio S Randall
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-12-07       Impact factor: 3.738

Review 4.  Oxidative stress and diabetic complications.

Authors:  Ferdinando Giacco; Michael Brownlee
Journal:  Circ Res       Date:  2010-10-29       Impact factor: 17.367

Review 5.  Epidemiology of the insulin resistance syndrome.

Authors:  James B Meigs
Journal:  Curr Diab Rep       Date:  2003-02       Impact factor: 4.810

6.  Metabolic syndrome in adolescents with spinal cord dysfunction.

Authors:  Mindy Dopler Nelson; Lana M Widman; Richard Ted Abresch; Kimber Stanhope; Peter J Havel; Dennis M Styne; Craig M McDonald
Journal:  J Spinal Cord Med       Date:  2007       Impact factor: 1.985

7.  Sugar-sweetened beverages and prevalence of the metabolically abnormal phenotype in the Framingham Heart Study.

Authors:  Angela K Green; Paul F Jacques; Gail Rogers; Caroline S Fox; James B Meigs; Nicola M McKeown
Journal:  Obesity (Silver Spring)       Date:  2014-03-08       Impact factor: 5.002

8.  Growth hormone therapy improves exercise capacity in adult patients with Prader-Willi syndrome.

Authors:  L A Gondoni; L Vismara; P Marzullo; R Vettor; A Liuzzi; G Grugni
Journal:  J Endocrinol Invest       Date:  2008-09       Impact factor: 4.256

9.  Basal insulin resistance and secretion in Nigerians with type 2 diabetes mellitus.

Authors:  J M Oli; A A Adeyemo; G O Okafor; E N Ofoegbu; B Onyenekwe; C J Chukwuka; C N Onwasigwe; S Ufelle; G Chen; C N Rotimi
Journal:  Metab Syndr Relat Disord       Date:  2009-12       Impact factor: 1.894

10.  Changes in insulin sensitivity during leptin replacement therapy in leptin-deficient patients.

Authors:  Gilberto Paz-Filho; Karin Esposito; Barry Hurwitz; Anil Sharma; Chuanhui Dong; Victor Andreev; Tuncay Delibasi; Halil Erol; Alejandro Ayala; Ma-Li Wong; Julio Licinio
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-10-14       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.